Modified Mrna Transfection
Modified Mrna Transfection - Related Videos
02:57
Transfecting Primary Macrophages with Modified mRNA
0 Views •
2025
This video demonstrates the process of transfecting primary macrophages with modified mRNA encoding green fluorescent protein. These modified mRNAs, designed to reduce immunogenicity and improve its stability, ensure the successful transfection and subsequent expression of green fluorescent proteins, which is confirmed through fluorescence microscopy.
08:55
In vitro Transcription and Capping of Gaussia Luciferase mRNA Followed by HeLa Cell Transfection
0 Views •
Cited by 13 •
2012
This method describes high yield in vitro synthesis of both capped and uncapped mRNA from a linearized plasmid containing the Gaussia luciferase (GLuc) gene. The RNA is purified and a fraction of the uncapped RNA is enzymatically capped using the Vaccinia virus capping enzyme. In the final step, the mRNA is transfected into HeLa cells and cell culture supernatants are assayed for luciferase activity.
07:40
Gene Transfection toward Spheroid Cells on Micropatterned Culture Plates for Genetically-modified Cell Transplantation
0 Views •
Cited by 9 •
2015
This protocol describes a cell transplantation system using genetically modified, injectable spheroids. Cell spheroids are cultured on micropatterned culture plates and recovered after gene introduction using polyplex nanomicelles. This system facilitates prolonged transgene expression from the transplanted cells in host animals while maintaining the innate function of the cells.
07:28
An Introduction to Transfection
0 Views •
2023
Transfection is the process of inserting genetic material, such as DNA and double stranded RNA, into mammalian cells. The insertion of DNA into a cell enables the expression, or production, of proteins using the cells own machinery, whereas insertion of RNA into a cell is used to down-regulate the production of a specific protein by stopping translation. While the site of action for transfected RNA is the cytoplasm, DNA must be transported to the nucleus for effective transfection. There, the...
07:25
Transfection and Mutagenesis of Target Genes in Mosquito Cells by Locked Nucleic Acid-modified Oligonucleotides
0 Views •
Cited by 3 •
2010
Oligonucleotides can be used to site specifically substitute a single nucleotide of transfected target genes in both Anopheles gambiae and Anopheles stephensi cells.
FAQs
Chemically modified nucleosides can reduce innate immune sensing while supporting higher protein production. This matters because cells may otherwise detect introduced RNA as a signal and mount responses that interfere with expression. In immunology experiments, altering the RNA chemistry helps researchers distinguish the intended effects of the encoded protein from unwanted responses triggered by the delivery material itself.
Once delivered, the mRNA remains available in the cytoplasm for ribosomes to translate, so protein production does not require genomic integration or a change to cellular DNA. This separation is especially useful when investigators need controlled, temporary expression of an antigen, cytokine, or immune regulator. It allows host responses to be examined without permanently altering the cells’ genetic material.
Modified mRNA transfection can use lipid nanoparticles or electroporation to move the cargo across the cell membrane. These options represent different delivery formats within the same overall strategy: the key downstream event is cytoplasmic access, followed by ribosomal translation. Selecting between them is therefore relevant to how the RNA enters cells, while the encoded sequence determines which protein is produced.
Protein output depends on more than the encoded sequence. The RNA must reach the cytoplasm, remain suitable for translation, and avoid excessive innate immune sensing that can reduce production. Delivery format and nucleoside modification address these requirements from different angles: lipid nanoparticles or electroporation support entry, whereas chemical modification can improve expression by limiting sensing.
A typical workflow starts by selecting an mRNA sequence for the protein of interest, then introducing it with a lipid nanoparticle formulation or electroporation. After entry, researchers examine translation in the cytoplasm and assess the resulting protein or cellular response. This workflow can be adapted to express pathogen antigens, cytokines, or other immune regulators for defined experiments.
In infection research, the technique supports several linked applications rather than a single endpoint. Temporary pathogen-antigen expression can help investigate host responses, while cytokine or immune-regulator expression can support therapeutic strategy testing. The same programmable approach also contributes to mRNA vaccine development and rapid studies of emerging infectious diseases, where changing the encoded target can accelerate experimental design.